Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors.
John GridleyDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory Vaccine Center, Atlanta, GA, USA.ORCID 0009-0000-2800-5290
David PakDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory Vaccine Center, Atlanta, GA, USA.ORCID 0009-0000-9252-380X
Anuradha KumariDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory Vaccine Center, Atlanta, GA, USA.ORCID 0000-0003-1829-8215
Jacob ShupakDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory Vaccine Center, Atlanta, GA, USA.ORCID 0009-0006-9673-0762
Brantley HollandDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory Vaccine Center, Atlanta, GA, USA.ORCID 0000-0003-4907-4708
Yifeng ShiDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory Vaccine Center, Atlanta, GA, USA.ORCID 0009-0009-5763-0875
Sheetal TrivediCenter for Vaccines and Immunity, The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.
Yongtao WangLiver Center, Gastrointestinal Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Sudhir Pai KasturiDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory Vaccine Center, Atlanta, GA, USA.
Amit KapoorCenter for Vaccines and Immunity, The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.ORCID 0000-0002-8117-7347
Raymond T ChungLiver Center, Gastrointestinal Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Arash GrakouiDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory Vaccine Center, Atlanta, GA, USA. arash.grakoui@emory.edu.ORCID 0000-0002-6002-7518
Funding
Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
YNPRC NHP CLINICAL MEDICINE RESIDENCY PROGRAM - SUPPLEMENTP51RR000165 · NCRR · EMORY UNIVERSITY · PI WALLEN, KIM · 1985 to 2011
$114.0M
Protective immunity to HCV and rational vaccine designU19AI159819 · NIAID · EMORY UNIVERSITY · PI Arash Grakoui · 2021 to 2026
$16.6M
Training a New Generation of VaccinologistsT32AI074492 · NIAID · EMORY UNIVERSITY · PI Rama Rao Amara, Benjamin A Lopman · 2009 to 2026
$6.4M
Dynamics of antigen specific B and Tfh responses during acute and chronic HCVR01AI136533 · NIAID · EMORY UNIVERSITY · PI GRAKOUI, ARASH · 2018 to 2022
$3.8M
Immune correlates of protection against hepacivirus persistence.R01AI151175 · NIAID · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI KAPOOR, AMIT · 2021 to 2024
$2.5M
Animal Model to study heterogeneous outcomes of HCV Infection and PathogenesisR01AI183877 · NIAID · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI Amit Kapoor · 2024 to 2026
$2.4M
Viral Determinants of Chronic Hepacivirus InfectionR01AI185926 · NIAID · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI Amit Kapoor · 2024 to 2026
$2.0M
Investigating the role of intrahepatic plasma cells in the clearance of HCV infection: implications for rational vaccine designF32AI189066 · NIAID · EMORY UNIVERSITY · PI John Gridley · 2025 to 2026
Upon viral infection, the current paradigm of humoral immunity posits that germinal centre reactions occurring within secondary lymphoid organs (SLOs) yield effector plasma cells that subsequently traffic to infected organs or the bone marrow
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
iHALT unlocks liver functionality as a surrogate secondary lymphoid organ. · full record | Socratic